Medy-Tox Inc.
Financials
Valuation Metrics
Medy-Tox Inc.'s Market Cap is ₩4642B. At end of 2025 it was ₩8817B. Ranked #454 of 2,410 in KR market (top 19%), #164 of 1,631 on KOSDAQ (top 10%), #49 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 464.18B KRW | KR#454/2,410 Sec#49/231 |
| Revenue | 251.08B KRW | KR#914/2,410 Sec#50/231 |
| Net Income | 15.15B KRW | KR#814/2,410 Sec#54/231 |
| Total Assets | 571.87B KRW | KR#711/2,410 Sec#41/231 |
| Net Assets | 379.35B KRW | KR#615/2,410 Sec#39/231 |
| Employees | 776 | KR#325/2,410 Sec#28/231 |
| Value | ||
| P/E | 30.64x | KR#1,343/2,410 Sec#83/231 |
| P/B | 1.22x | KR#1,714/2,410 Sec#115/231 |
| PEG | 0.14x | KR#516/2,410 Sec#30/231 |
| P/S | 1.85x | KR#1,823/2,410 Sec#105/231 |
| EV/EBITDA | 36.06x | KR#1,285/2,410 Sec#82/231 |
| FCF Yield | 9.86% | KR#651/2,410 Sec#27/231 |
| Profitability | ||
| ROE | 3.99% | KR#1,219/2,410 Sec#85/231 |
| ROA | 2.65% | KR#1,097/2,410 Sec#81/231 |
| Op. Margin | 6.91% | KR#735/2,410 Sec#58/231 |
| Revenue Growth | 7.01% | KR#1,065/2,410 Sec#103/231 |
| Earnings Growth | 216.81% | KR#231/2,410 Sec#14/231 |
| Financial Health | ||
| Debt Ratio | 50.75% | KR#965/2,410 Sec#111/231 |
| Total Debt | 208.24B KRW | KR#504/2,410 Sec#26/231 |
| FCF | 45.75B KRW | KR#323/2,410 Sec#18/231 |
| Cash | 46.93B KRW | KR#771/2,410 Sec#47/231 |
| Current Ratio | 1.03x | KR#1,677/2,410 Sec#169/231 |
| Net Debt/EBITDA | 9.30x | KR#1,196/2,410 Sec#87/231 |
| Dividend | ||
| Div. Yield | 1.92% | KR#955/2,410 Sec#49/231 |
| Div. Growth | 9.09% | KR#619/2,410 Sec#34/231 |
| Performance | ||
| 1Y Return | -47.09% | KR#1,909/2,410 Sec#168/231 |
| 1M Return | -4.50% | KR#637/2,410 Sec#66/231 |
| From 52W High | -54.93% | KR#1,356/2,410 Sec#110/231 |
| 1Y MDD | -54.18% | KR#1,143/2,410 Sec#95/231 |
| Trading | ||
| Volume | 7,023 shares | KR#1,987/2,410 Sec#203/231 |
| Trading Value | 446.8M KRW | KR#852/2,410 Sec#90/231 |
| Foreign Own. | 14.32% | KR#335/2,410 Sec#22/231 |
| Per Share | ||
| EPS | 2,076 KRW | KR#439/2,410 Sec#28/231 |
| BPS | 51,976 KRW | KR#258/2,410 Sec#16/231 |
Company Info
Established in 2000 and listed on KOSDAQ in 2009, Meditox engages in the research, development, manufacturing, and sale of Botulinum Toxin Type A and biopharmaceuticals. The company's main products are Meditoxin Inj., Coretox, and Innotox, developed with proprietary original technology. With the KFDA product approval for Neurtoxin in 2023, it is expanding into domestic and international markets while diversifying its portfolio with hyaluronic acid fillers, liquid toxin formulations for US entry, and genetically recombinant toxins. Meditox is headquartered in Cheongwon-gun, Chungcheongbuk-do.